The early results of a COMPASS Pathways clinical trial quell some concerns related to the safety of psychedelic therapy for individuals with bipolar disorder.
As psychedelic-assisted therapies near FDA approval, questions remain about cost, who’s paying, and how much it saves patients and insurers in the long run.
In an era where thought leaders are minted by social media metrics, some influencers may be one viral video away from being tomorrow’s psychedelic luminaries.
UNIFY founder Adil Kassam discusses how technology coupled with global group meditation can facilitate synchronized transformational experiences among millions of people.
The medicalization of psychedelics may be changing people’s minds, but can these developments result in deeper changes in how we view or access medicine?
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions.
**Contribute to the Future of Psychedelics** Make an investment in a healthy psychedelic future by supporting this community-funded initiative. For the last 3 years, Lucid News has been providing indispensable journalism covering the psychedelic field. We are now turning to our readers to continue building. We understand that not everyone is in a position to pay for this vital information, but if you are, we need you. *Make an investment in quality journalism, so others can benefit. You can give just once or monthly. Thank you.*
**Contribute to the Future of Psychedelics** Make an investment in a healthy psychedelic future by supporting this community-funded initiative. For the last 3 years, Lucid News has been providing indispensable journalism covering the psychedelic field. We are now turning to our readers to continue building. We understand that not everyone is in a position to pay for this vital information, but if you are, we need you. *Make an investment in quality journalism, so others can benefit. You can give just once or monthly. Thank you.*